Browsing Tag
Incyte
18 posts
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins
Incyte’s mutCALR antibody shows promise in myelofibrosis and ET. Find out what ASH 2025 data reveals about INCA033989’s future potential.
Toddlers get a breakthrough eczema treatment as FDA clears Arcutis’ ZORYVE cream 0.05%
Find out how Arcutis’ FDA-approved ZORYVE 0.05% cream is reshaping the pediatric eczema market and investor confidence in 2025.
Formation Bio hires ex-Pfizer and BenevolentAI leaders to supercharge its AI-driven drug development model
Formation Bio bolsters its leadership team with top biotech and pharma veterans to fast-track its AI-driven drug development model.
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
Hope for alopecia patients? Lilly’s baricitinib delivers significant hair regrowth in adolescents
Eli Lilly and Company (Lilly), in collaboration with Incyte, has reported significant progress in the treatment of severe…
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing…
Niktimvo FDA approval brings new hope for chronic graft-versus-host disease patients
The U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host…
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on…
Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo…